Kane Investment Management Inc. Sells 483 Shares of Eli Lilly and Company $LLY

Kane Investment Management Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,753 shares of the company’s stock after selling 483 shares during the quarter. Eli Lilly and Company comprises about 1.5% of Kane Investment Management Inc.’s investment portfolio, making the stock its 9th largest holding. Kane Investment Management Inc.’s holdings in Eli Lilly and Company were worth $2,929,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Blume Capital Management Inc. increased its holdings in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $35,000. TD Capital Management LLC boosted its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares in the last quarter. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $54,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,022.00 on Friday. The stock’s 50 day moving average is $820.93 and its 200 day moving average is $779.85. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market cap of $966.19 billion, a P/E ratio of 66.80, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,032.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Guggenheim reaffirmed a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. UBS Group raised their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $999.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.